GKWIM
VTGN icon

Gerber Kawasaki Wealth & Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5
Closed – – 1099
2021
Q3 		$0 Buy
+5
New +$435 ﹤0.01% 1238

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's VTGN Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of VistaGen Therapeutics (VTGN) in Q4 2021, closing a stake of 5 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in VTGN in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 106 funds tracked by Wall St. Rank hold VTGN as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining VistaGen Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 5 VistaGen Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's VistaGen Therapeutics position peaked at $0 in Q3 2021.
  • 106 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.